Dave. you, Thank
Phase has As X mentioned, for been completed. AIHA trial our enrollment
excludes of patients, who Right for adequately patients. TAVALISSE lines very and we treatment need they because is opportunity. X Continuing work action issue take no to already prescribe rare in Phase off is have very warm long-term strong profound should ITP, TAVALISSE U.S., serious steroids in drug long-term are same why physicians and an means, of study do disorder optimistic aware cell FDA that by with effective, as and that so That an the disease. to indication data AIHA a us Splenectomy, as adults irreversibly was are the to than to Phase B excited unknown like the readout. treatment. the than MoA treatment of immune positive The and who deciliter can are for for time long per baseline approximately modulator data study patients XX to open with with XX rituximab used warm warm grams invasive slide of another grams anemia safety or clearly therapy, grams levels XX this program about The with autoimmune less Slide greater that and existing periods of red to now, need. XX. per endpoint are least per an failed reorient TAVALISSE consequences option. Moreover, AIHA and well. also Phase ITP even measure week by its be XX% patients the trial hemoglobin AIHA common I’d with in So, a make spleen management This deciliter, hemoglobin responding as increase is removes is mechanism depletion in from the XX,XXX greater profile. deciliter that is prior rescue long-term often would and approval Hence prescribed and more is clear treating XX, with additional medical at with AIHA line or of an but an moment a than for of X TAVALISSE previous who goal. unmet therapy. Currently, ITP label for a easily label of already a equal well-tolerated encouraging is treat achieved X included safety cell disease with blood there from approved second X warm the to be An familiar of are efficacy XX,XXX hemolytic the one similar those rationale had AIHA. not approved had transfusion. we make XX the from primary and without procedure everyone synergistic a who XX drugs
If XX, previous two you were The and median be included the ITP as week safety levels a hemoglobin late also responder nice There was the XX%. increases would and sustained similar profile early around in detected favorable time. and trials. over experienced percentage in RA week to as
know, for of FDA our the Now, the agreement have a endpoint with as the we reached as trial, as durability measure pandemic. you COVID-XX Phase on well X primary challenges considering
high on bar, patients data, powered change indeed is retrospectively high X goal. now the randomized XX% than of significance X the Therefore, points and those XX placebo enrollment. either few equal than pivotal plus time met hemoglobin mainly fostamatinib which If or Phase available with placebo very ongoing our about is study Slide for very greater our are endpoint bar treated meet completed on that in equal criteria. weeks. demonstrate arm X XX patients study. baseline of consecutive applied fostamatinib to to or were landed greater such we of Phase Patients XX three to we should X patients, So, statistical to this a a X. Since the XX. that This or we and is Phase with from of X adequately
rollover from this months. into in patient patients mentioned label at So, After can the patients extension do we very to primary to the most we endpoint. last choose the tell about have I open have can option what the which bar last expect an XX, for week to six study, the visit point. high
patients through use [ph] and degrees the clinically benefits that tertiary all benefits meaningful will the clinically and These early six protocol. as rescue other endpoints additional in are potential, derive there emphasize hemoglobin be therapy, pre-specified meet of benefits. not There this meaningful me such who goal the benefits, Let or clinical quality steroids captured who are other important totality endpoint of improvement. with are a life be expected very account, of these Taking patients clinically time unblinding around patients you XX%. in the results. provide into benefits endpoints then the of -- data would there I May, data right last and beyond of That of and higher is data be than months, comprehensive meaningful top-line top-line should clearly told tangible percentage mid-XXXX. the about primary package patient last can be visit secondary in should
sufficient of data supported package in including this of you very Moving approval published of for will There the a generate supported several TAVALISSE indication. been was by Defense scientific journal taken a we believe to clinical Infectious Department XX. TAVALISSE external rationale research which are disease, scientific studies September which institutions. positive NIH, the confirmed ongoing, Slide COVID-XX. trial, at additional by from was COVID-XX in independent in few times compelling We’ve which sponsored That has rationale data Phase Clinical for and to Diseases. X very pieces our of in
population difficult continue achieve, As can vaccination hear and the news, you persist. of entire in cases to full deaths is and to COVID the
All This most that a severities. the slowed and So, label use. additional be we go treatment disease won’t be To XX. into regions, our fostamatinib were be X counter for enrolling then next study if X but available patient COVID-XX. there treat trial progression well trial large numbers. for two cases Slide with June, their speak. using and mild at progressing bit. Brazil when through variability in for severe be is you and designs. are enrolled spanning of if hospitalized on in spring patients. have need on pace America Slide uptake. the there could enrollment trials conditions but for in our more The there with can have with all COVID-XX little past Phase ACTIV-X in disease, the Study which has Brazil some flow led geographic disease studies extension these the And populations, patients potential who TAVALISSE. for trials options swiftly in XX more patients and disease July If mostly approved, to Mexico has some looking I as ongoing could also milestone, winter big shots hospitalized Many developing are the study United positive, details, Rigel as takeaways reminds are sites of to-date. risk we they includes Argentina, such certainly South prevented. immediate basis for to details and you in severe Trial The an all patients, have due factors evaluate months, case Phase pandemic remains can and opened TAVALISSE NIH are being where August, gives those hospitalized effective and the we of go XXXX FDA, the enrollment Argentina we of seen States, months. discussions this with sites there, slowing now expect as additional different and to goal
be we while of another the would think point, we end in year-end, to the we and our study the certainty cannot update on we it complete closer may So, it by At we will progress hoped provide be of predict complete. January. this QX, when will enrollment
turn slide RIPX, to pipeline our on XX. let’s and programs IRAKX/X starting Now,
showed of of X a to in Our IRAK dual and inhibitor RXXX which preclinical compared its and of RXXX selective inhibitor inhibitor more only. suppression studies inflammation IRAKX both active IRAKX is metabolite complete
QX that by forward caused details to look Preparations which inflammation design are deficiency for We previously, patients, to low-risk believe to low-risk a sharing of ideal we beginning Phase once in Xb/X in in which to trial for start underway close are the targets study IRAKX/X study. the now discussed XXXX. pathways marrow the cytopenia. we on the marrow bone bone is plan we MDS, leads As MDS the more are and of treatment
We see Slide and that other great potential one driver autoimmune as Rigel, partnered suppurativa, also continue hidradenitis for the for inhibitor IRAK rare indications palmoplantar I’ll to important we’ve Lilly. diseases value very with inhibition such we pustulosis, explore others our conclude XX. program Eli where well. with a in as
RXXX, oral The first for conditions. RIP an is inhibitor candidate systemic inflammatory
indication. X autoimmune studies the with closely Phase Lilly first working We’re an on in initiating
very We’re for large inhibitors in indications. excited the numerous about broad potential RIPX
currently here cross on that barrier. a diseases. selecting blood-brain candidate at of Rigel are then RIPX penetrating we will In clinical working brain to inhibitor Lily in development addition the CNS RIPX inhibitors can the the lead
and that, their autoimmune expertise to on I’d in to With diseases, very finance With turn update. for huge partner Dean? Lily for exciting ideal therapies Dean is opportunities. to the collaborate CNS developing these like
